csirt@kutim:~/threat-intel/cve/CVE-2025-27145

Katalog CVE

CVSS 6.1 · Medium EPSS 0,47%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') pada 9001 copyparty. Skor CVSS 3.1 6.1 (Medium) menurut NVD.

Deskripsi (NVD)

copyparty, a portable file server, has a DOM-based cross-site scripting vulnerability in versions prior to 1.16.15. The vulnerability is considered low-risk. By handing someone a maliciously-named file, and then tricking them into dragging the file into copyparty's Web-UI, an attacker could execute arbitrary javascript with the same privileges as that user. For example, this could give unintended read-access to files owned by that user. The bug is triggered by the drag-drop action itself; it is not necessary to actually initiate the upload. The file must be empty (zero bytes). Note that, as a general-purpose webserver, it is intentionally possible to upload HTML-files with arbitrary javascript in `<script>` tags, which will execute when the file is opened. The difference is that this vulnerability would trigger execution of javascript during the act of uploading, and not when the uploaded file was opened. Version 1.16.15 contains a fix.

Rincian

Terbit di NVD
25 Februari 2025
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
6.1 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
CWE-83: Improper Neutralization of Script in Attributes in a Web Page
EPSS (30 hari)
0,47% peluang dieksploitasi; lebih tinggi dari 38,8% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
9001 copyparty Semua versi sebelum 1.16.15

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.